
    
      A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging
      Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor
      Agonist (SB-497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving
      Multiple Cycles of Chemotherapy
    
  